Nippon India Pharma Fund Direct Growth

Fund Overview

Fund Size

₹7,875 Cr

Expense Ratio

0.92%

ISIN

INF204K01I50

Minimum SIP

₹1,000

Exit Load

1.00%

Inception Date

01 Jan 2013

About this fund

Nippon India Pharma Fund Direct Growth is a Sector - Healthcare mutual fund schemes offered by Nippon India Mutual Fund. This fund has been in existence for 13 years, 1 months and 20 days, having been launched on 01-Jan-13.
As of 20-Feb-26, it has a Net Asset Value (NAV) of ₹566.50, Assets Under Management (AUM) of 7875.40 Crores, and an expense ratio of 0.92%.

Nippon India Pharma Fund Direct Growth has given a CAGR return of 17.29% since inception.
The fund's asset allocation comprises around 98.97% in equities, 0.00% in debts, and 1.03% in cash & cash equivalents.
You can start investing in Nippon India Pharma Fund Direct Growth with a SIP of ₹1000 or a Lumpsum investment of ₹5000.

Performance against Category Average

In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.

1 Year

+8.37%

+8.20% (Cat Avg.)

3 Years

+24.12%

+23.39% (Cat Avg.)

5 Years

+16.34%

+15.44% (Cat Avg.)

10 Years

+15.13%

+13.48% (Cat Avg.)

Since Inception

+17.29%

— (Cat Avg.)

Portfolio Summaryas of 31st January 2026

Equity	₹7,794.08 Cr	98.97%
Others	₹81.32 Cr	1.03%

Top Holdings

All Holdings

Equity

Debt & Others

Name	Type	Amount	Holdings
Sun Pharmaceuticals Industries Ltd	Equity	₹998.08 Cr	12.67%
Lupin Ltd	Equity	₹620.87 Cr	7.88%
Divi's Laboratories Ltd	Equity	₹514.79 Cr	6.54%
Dr Reddy's Laboratories Ltd	Equity	₹477.02 Cr	6.06%
Cipla Ltd	Equity	₹462.75 Cr	5.88%
Apollo Hospitals Enterprise Ltd	Equity	₹451.59 Cr	5.73%
Medplus Health Services Ltd	Equity	₹289.8 Cr	3.68%
Vijaya Diagnostic Centre Ltd	Equity	₹276.75 Cr	3.51%
Ajanta Pharma Ltd	Equity	₹266.87 Cr	3.39%
GlaxoSmithKline Pharmaceuticals Ltd	Equity	₹219.32 Cr	2.78%
Sai Life Sciences Ltd	Equity	₹213.44 Cr	2.71%
Aurobindo Pharma Ltd	Equity	₹205.63 Cr	2.61%
Abbott India Ltd	Equity	₹204.5 Cr	2.60%
Ipca Laboratories Ltd	Equity	₹200.73 Cr	2.55%
Mankind Pharma Ltd	Equity	₹192.68 Cr	2.45%
J.B. Chemicals & Pharmaceuticals Ltd	Equity	₹186.88 Cr	2.37%
Thyrocare Technologies Ltd	Equity	₹184.47 Cr	2.34%
Alkem Laboratories Ltd	Equity	₹183.77 Cr	2.33%
Dr. Lal PathLabs Ltd	Equity	₹171.71 Cr	2.18%
Narayana Hrudayalaya Ltd	Equity	₹163.34 Cr	2.07%
Gland Pharma Ltd	Equity	₹147.83 Cr	1.88%
Pfizer Ltd	Equity	₹145.24 Cr	1.84%
Max Healthcare Institute Ltd Ordinary Shares	Equity	₹118.77 Cr	1.51%
Emcure Pharmaceuticals Ltd	Equity	₹109.25 Cr	1.39%
Suraksha Diagnostic Ltd	Equity	₹103.62 Cr	1.32%
Fortis Healthcare Ltd	Equity	₹94 Cr	1.19%
Sanofi India Ltd	Equity	₹92.52 Cr	1.17%
Triparty Repo	Cash - Repurchase Agreement	₹90.82 Cr	1.15%
Sanofi Consumer Healthcare India Ltd	Equity	₹90.74 Cr	1.15%
Syngene International Ltd	Equity	₹89.17 Cr	1.13%
Biocon Ltd	Equity	₹81.41 Cr	1.03%
Akums Drugs and Pharmaceuticals Ltd	Equity	₹66.6 Cr	0.85%
Anthem Biosciences Ltd	Equity	₹63.44 Cr	0.81%
AstraZeneca Pharma India Ltd	Equity	₹53.5 Cr	0.68%
Indoco Remedies Ltd	Equity	₹39.91 Cr	0.51%
Concord Biotech Ltd	Equity	₹13.13 Cr	0.17%
Net Current Assets	Cash	₹-9.56 Cr	0.12%
Cash Margin - Ccil	Cash - Repurchase Agreement	₹0.07 Cr	0.00%

Allocation By Market Cap (Equity)

Other Allocation

Equity Sector

Debt & Others

Sector	Amount	Holdings
Healthcare	₹7,794.08 Cr	98.97%

Risk & Performance Ratios

Fund Managers

Sailesh Raj Bhan

Since April 2005

Kinjal Desai

Since May 2018

Lokesh Maru

Since September 2025

Divya Sharma

Since September 2025

Additional Scheme Detailsas of 31st January 2026

ISIN

INF204K01I50

Expense Ratio

0.92%

Exit Load

1.00%

Fund Size

₹7,875 Cr

Age

13 years 1 month

Lumpsum Minimum

₹5,000

Fund Status

Open Ended Investment Company

Benchmark

BSE Healthcare TR INR

Investment Objective

To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.

Tax Treatment

Capital Gains Taxation:

Dividend Taxation:

Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Similar Sector - Healthcare Funds

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Groww BSE Hospitals ETF Very High Risk	-	-	-	-
Mirae Asset Nifty 500 Healthcare ETF Very High Risk	-	-	-	-
Bandhan Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹279.60 Cr	-
Bandhan Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹279.60 Cr	-
Baroda BNP Paribas Health and Wellness Fund Direct Growth Very High Risk	0.6%	1.0%	₹544.81 Cr	-
Baroda BNP Paribas Health and Wellness Fund Regular Growth Very High Risk	2.3%	1.0%	₹544.81 Cr	-
Bajaj Finserv Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹307.34 Cr	5.0%
Bajaj Finserv Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹307.34 Cr	6.8%
PGIM India Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹88.38 Cr	9.6%
PGIM India Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹88.38 Cr	7.9%
WhiteOak Capital Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹491.85 Cr	11.0%
WhiteOak Capital Pharma and Healthcare Fund Direct Growth Very High Risk	0.7%	1.0%	₹491.85 Cr	12.9%
DSP Nifty Healthcare ETF Regular Growth Very High Risk	0.2%	-	₹10.44 Cr	9.2%
Kotak Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹451.35 Cr	10.5%
Kotak Healthcare Fund Regular Growth Very High Risk	2.3%	0.0%	₹451.35 Cr	8.7%
HDFC Pharma and Healthcare Fund Regular Growth Very High Risk	2.1%	1.0%	₹1875.89 Cr	12.5%
HDFC Pharma and Healthcare Fund Direct Growth Very High Risk	0.9%	1.0%	₹1875.89 Cr	13.8%
Nippon India Pharma Fund Direct Growth Very High Risk	0.9%	1.0%	₹7875.40 Cr	8.4%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Regular Growth Very High Risk	1.9%	1.0%	₹6658.41 Cr	6.4%
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth Very High Risk	1.0%	1.0%	₹6658.41 Cr	7.3%
DSP Healthcare Fund Direct Growth Very High Risk	0.6%	0.0%	₹2971.07 Cr	0.0%
DSP Healthcare Fund Regular Growth Very High Risk	1.9%	0.0%	₹2971.07 Cr	-1.3%
LIC MF Healthcare Fund Direct Growth Very High Risk	1.1%	1.0%	₹78.65 Cr	3.3%
LIC MF Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹78.65 Cr	2.1%
quant Healthcare Fund Direct Growth Very High Risk	0.8%	1.0%	₹340.56 Cr	6.1%
quant Healthcare Fund Regular Growth Very High Risk	2.4%	1.0%	₹340.56 Cr	4.4%
UTI Healthcare Fund Direct Growth Very High Risk	1.3%	1.0%	₹1055.01 Cr	8.6%
SBI Healthcare Opportunities Fund Direct Growth Very High Risk	0.9%	0.0%	₹3822.73 Cr	7.8%
Tata India Pharma & Healthcare Fund Regular Growth Very High Risk	2.1%	0.0%	₹1239.57 Cr	6.1%
Tata India Pharma & Healthcare Fund Direct Growth Very High Risk	0.7%	0.0%	₹1239.57 Cr	7.7%
ICICI Prudential Nifty Healthcare ETF Very High Risk	0.1%	-	₹135.28 Cr	9.4%
SBI Healthcare Opportunities Fund Regular Growth Very High Risk	1.9%	0.0%	₹3822.73 Cr	6.7%
Nippon India Pharma Fund Regular Growth Very High Risk	1.8%	1.0%	₹7875.40 Cr	7.4%
UTI Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹1055.01 Cr	7.6%
Axis NIFTY Healthcare ETF Very High Risk	0.3%	-	₹19.11 Cr	9.1%
Nippon India Nifty Pharma ETF Very High Risk	0.2%	-	₹1007.47 Cr	8.6%
Mirae Asset Healthcare Fund Regular Growth Very High Risk	1.9%	1.0%	₹2639.92 Cr	8.4%
Mirae Asset Healthcare Fund Direct Growth Very High Risk	0.5%	1.0%	₹2639.92 Cr	10.0%
ITI Pharma and Healthcare Fund Regular Growth Very High Risk	2.4%	0.0%	₹210.46 Cr	-0.6%
ITI Pharma and Healthcare Fund Direct Growth Very High Risk	0.5%	0.0%	₹210.46 Cr	1.3%
Aditya Birla Sun Life Nifty Healthcare ETF Very High Risk	0.2%	-	₹49.65 Cr	9.3%
Aditya Birla Sun Life Pharma & Healthcare Fund Regular Growth Very High Risk	2.3%	1.0%	₹812.03 Cr	7.3%
Aditya Birla Sun Life Pharma & Healthcare Fund Direct Growth Very High Risk	1.0%	1.0%	₹812.03 Cr	8.7%
Motilal Oswal S&P BSE Healthcare ETF Very High Risk	0.2%	-	₹40.21 Cr	7.3%

About the AMC

Nippon India Mutual Fund

022-6808 7000/18602660111

https://mf.nipponindiaim.com/

Total AUM

₹7,25,431 Cr

Address

4th Floor, Tower A, Peninsula Business Park, Mumbai, 400 013

Other Funds by Nippon India Mutual Fund

Fund name	Expense Ratio	Exit Load	Fund size	1Y
Nippon India Nifty India Manufacturing Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹36.80 Cr	-
Nippon India MNC Fund Direct Growth Very High Risk	1.2%	1.0%	₹425.65 Cr	-
Nippon India Income Plus Arbitrage Active Fund of Fund Direct Growth Moderate Risk	0.1%	0.0%	₹623.45 Cr	-
Nippon India BSE Sensex Next 30 Index Fund Direct Growth Very High Risk	0.2%	0.0%	₹38.01 Cr	-
Nippon India Nifty 500 Low Volatility 50 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹20.44 Cr	-
Nippon India Nifty 500 Quality 50 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹43.18 Cr	-
Nippon India Active Momentum Fund Direct Growth Very High Risk	0.7%	1.0%	₹338.26 Cr	-
Nippon India Nifty Auto Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹40.39 Cr	26.8%
Nippon India Nifty Realty Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹31.62 Cr	-4.3%
Nippon India CRISIL-IBX AAA Financial Services - Dec 2026 Index Fund Regular Growth Moderate Risk	0.1%	0.0%	₹98.23 Cr	7.7%
Nippon India CRISIL-IBX AAA Financial Services - Jan 2028 Index Fund Regular Growth Low to Moderate Risk	0.1%	0.0%	₹85.07 Cr	8.1%
Nippon India Nifty 500 Momentum 50 Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹1033.35 Cr	8.4%
Nippon India Nifty 500 Equal Weight Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹401.77 Cr	11.0%
Nippon India Fixed Maturity Plan - XLVI - Series 5 - 1868 Days Direct Growth High Risk	-	0.0%	-	-
Nippon India Fixed Maturity Plan - XLVI - Series 2 - 366 Days Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Maturity Plan - XLVI - Series 3 - 368 Days Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Maturity Plan - XLVI - Series 2 - 367 Days Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Nifty IT Index Fund Direct Growth Very High Risk	0.3%	0.0%	₹213.47 Cr	-20.0%
Nippon India Nifty Bank Index Fund Direct Growth Very High Risk	0.2%	0.0%	₹185.38 Cr	24.6%
Nippon India Fixed Maturity Plan - XLVI - Series 1 - 92 Days Direct Growth Moderately High risk	-	0.0%	-	-
Nippon India Innovation Fund Direct Growth Very High Risk	0.6%	1.0%	₹2696.94 Cr	13.2%
Nippon India Fixed Horizon Fund - XLV - Series 2 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Horizon Fund XLII Series 1 Direct Growth Moderate Risk	-	-	-	-
Nippon India Fixed Horizon Fund - XLV - Series 3 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Horizon Fund XLII Series 7 Direct Growth Moderate Risk	-	-	-	-
Nippon India Fixed Horizon Fund XLI Series 6 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Horizon Fund XLII Series 5 Direct Growth Moderate Risk	-	-	-	-
Nippon India Fixed Horizon Fund XLI Series 7 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Horizon Fund - XLIII - Series 4 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Horizon Fund XLII Series 6 Direct Growth Moderate Risk	-	-	-	-
Nippon India Interval Fund Quarterly Series I Direct Growth Low Risk	-	0.0%	₹2.33 Cr	5.7%
Nippon India Fixed Horizon Fund XXXX Series 10 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Horizon Fund XLIV Series 4 Direct Growth Low Risk	-	-	₹51.85 Cr	6.9%
Nippon India Fixed Horizon Fund XLIV Series 3 Direct Growth Moderate Risk	-	-	-	-
Nippon India Interval Fund Annual Series I Direct Growth Low Risk	-	0.0%	₹3.06 Cr	7.0%
Nippon India Fixed Horizon Fund XLIV Series 5 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Horizon Fund - XLIII - Series 1 Direct Growth Low Risk	-	0.0%	₹220.19 Cr	7.1%
Nippon India Fixed Horizon Fund XLIV Series 1 Direct Growth Low to Moderate Risk	-	0.0%	₹72.20 Cr	7.8%
Nippon India Fixed Horizon Fund - XLIII - Series 3 Direct Growth Moderate Risk	-	-	-	-
Nippon India Fixed Horizon Fund XLI Series 5 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Horizon Fund XLII Series 3 Direct Growth Moderate Risk	-	-	-	-
Nippon India Fixed Horizon Fund XLIII Series 5 Direct Growth Low to Moderate Risk	-	0.0%	₹184.13 Cr	7.9%
Nippon India Fixed Horizon Fund XXXIX Series 12 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Horizon Fund - XLIII - Series 2 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Fixed Horizon Fund XLI Series 3 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Capital Protection Oriented Fund II Plan A Direct Growth Low Risk	-	-	₹40.32 Cr	9.7%
Nippon India Interval Fund Quarterly Series III Direct Growth Low Risk	-	0.0%	₹2.74 Cr	5.8%
Nippon India Fixed Horizon Fund XLI Series 13 Direct Growth Moderate Risk	-	-	-	-
Nippon India Fixed Horizon Fund XXXX Series 9 Direct Growth Moderate Risk	-	0.0%	-	-
Nippon India Interval Fund Quarterly Series II Direct Growth Moderate Risk	-	0.0%	₹14.58 Cr	5.9%

Risk Level

Your principal amount will be at Very High Risk

Take control of your wealth

Track and Analyse all your investments with Dezerv

Rated ★ 4.3+ on

Still got questions?
We're here to help.

What is the current NAV of Nippon India Pharma Fund Direct Growth?

The NAV of Nippon India Pharma Fund Direct Growth, as of 20-Feb-2026, is ₹566.50.

What are the returns of Nippon India Pharma Fund Direct Growth?

The fund has generated 8.37% over the last 1 year and 24.12% over the last 3 years. However, this does not guarantee that the fund will perform similarly in the future.

What is the portfolio composition of Nippon India Pharma Fund Direct Growth?

The fund's allocation of assets is distributed as 98.97% in equities, 0.00% in bonds, and 1.03% in cash and cash equivalents.

Who manages the Nippon India Pharma Fund Direct Growth?

The fund managers responsible for Nippon India Pharma Fund Direct Growth are:-

Sailesh Raj Bhan
Kinjal Desai
Lokesh Maru
Divya Sharma

Disclaimer: Mutual Fund investments are subject to market risks, read all scheme-related documents carefully. The NAVs of the schemes may go up or down depending upon the factors and forces affecting the securities market including the fluctuations in the interest rates. The past performance of the mutual funds is not necessarily indicative of the future performance of the schemes. Investors are requested to review the prospectus carefully and obtain expert professional advice with regard to specific legal, tax and financial implications of the investment/participation in the scheme.

;

©2021-2026 Dezerv. All Rights Reserved

Dezerv Investments Pvt. Ltd. is a Portfolio Manager with SEBI Registration no. INP000007377, a member of BSE with SEBI Stock Broker Registration no. INZ000303136, and an Investment Manager to Category - I AIF-VCF-Angel Fund with SEBI Registration no. IN/AIF1/22-23/1066.

Mutual Fund distribution services are offered through Dezerv Distribution Services Pvt Limited, a wholly owned subsidiary with AMFI Registration No.: ARN -248439. **Mutual fund investments are subject to market risks, read all scheme related documents carefully.** Terms and conditions of the website are applicable. Privacy policy of the website is applicable.

Nippon India Pharma Fund Direct Growth

Fund Overview